Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C1S | P09871 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL589692 | 0.92 | SMN1; SMN2 (0.33) | C1S | |
| SCHEMBL589889 | 0.86 | GAA (0.41) | AKR1C3NOTUM | |
| Trifluoroacetic Acid SCHEMBL9902969 | 0.86 | MAPT (0.31) | — | |
| SCHEMBL4071829 | 0.86 | MAPT (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL2672359 | 0.81 | — | — | |
| Trifluoroacetic Acid SCHEMBL589653 | 0.81 | FFAR1 (0.34) | C1SRAB9AAKR1C3 | |
| Trifluoroacetic Acid SCHEMBL589361 | 0.81 | FFAR1 (0.34) | C1SRAB9AAKR1C3 | |
| Trifluoroacetic Acid SCHEMBL589654 | 0.81 | FFAR1 (0.34) | C1SRAB9AAKR1C3 | |
| Trifluoroacetic Acid SCHEMBL589362 | 0.81 | FFAR1 (0.34) | C1SRAB9AAKR1C3 | |
| Trifluoroacetic Acid SCHEMBL2672365 | 0.81 | CNR1 (0.31) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604039-B2 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | C1S 1094/4885RAB9A 2130/4885AKR1C3 456/4885 |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | DPYD, DHFR, TPMT | C1S 260/4885RAB9A 3320/4885AKR1C3 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.